SGLT2 versus DPP4 inhibitors for type 2 diabetes

被引：15
|
作者：
Scheen, Andre J. [1 ,2 ]
机构：
[1] CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium
[2] CHU Sart Tilman, Dept Med, Clin Pharmacol Unit, B-4000 Liege, Belgium
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2013年 / 1卷 / 03期
关键词：
CANAGLIFLOZIN;
D O I：
10.1016/S2213-8587(13)70095-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：168 / 170
页数：4
相关论文
共 50 条
  • [31] Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus
    Y. Suzuki
    H. Kaneko
    A. Okada
    R. Ohno
    I. Yokota
    K. Fujiu
    T. Jo
    N. Takeda
    H. Morita
    K. Node
    H. Yasunaga
    I. Komuro
    Journal of Endocrinological Investigation, 2024, 47 : 1261 - 1270
  • [32] Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus
    Suzuki, Y.
    Kaneko, H.
    Okada, A.
    Ohno, R.
    Yokota, I.
    Fujiu, K.
    Jo, T.
    Takeda, N.
    Morita, H.
    Node, K.
    Yasunaga, H.
    Komuro, I.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (05) : 1261 - 1270
  • [33] Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes
    Au, Philip C. M.
    Tan, Kathryn C. B.
    Cheung, Bernard M. Y.
    Wong, Ian C. K.
    Wong, Ying
    Cheung, Ching-Lung
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (04): : E1719 - E1726
  • [34] THE COMPARISON OF SGLT2 INHIBITORS AND DPP-4 INHIBITORS ON HEALTH CARE EXPENDITURE AND UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Wagner, T.
    Dixon, D. L.
    Salgado, T. M.
    VALUE IN HEALTH, 2020, 23 : S117 - S117
  • [35] Cardiovascular outcomes in patients with type 2 diabetes who added either GLP1 receptor agonists or DPP4 inhibitors to SGLT2 inhibitor therapy
    Bykov, Katsiaryna
    Kim, Seoyoung
    Dave, Chintan
    Levin, Raisa
    Wexler, Deborah
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 98 - 98
  • [36] Comparison of SGLT2 inhibitors versus DPP-4 inhibitors as combination with metformin in patients with acute myocardial infarction with diabetes
    Lyu, Y.
    Oh, S.
    Kim, J.
    Jeong, M.
    Kim, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S474 - S475
  • [37] Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
    Bailey, Clifford J.
    Del Prato, Stefano
    Wei, Cheryl
    Reyner, Daniel
    Saraiva, Gabriela
    DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2564 - 2569
  • [38] SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
    Korbut, Anton I.
    Taskaeva, Iuliia S.
    Bgatova, Nataliya P.
    Muraleva, Natalia A.
    Orlov, Nikolai B.
    Dashkin, Maksim V.
    Khotskina, Anna S.
    Zavyalov, Evgenii L.
    Konenkov, Vladimir I.
    Klein, Thomas
    Klimontov, Vadim V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [39] The Neuroprotective Effects of DPP-4 and SGLT2 Inhibitors in Type 2 Diabetes: Possible Mechanism for Halting Cognitive Deterioration
    Osman, Shams T.
    Hamdy, Noha A.
    El Feky, Amr Y.
    El-Khordagui, Labiba K.
    El-Yazbi, Ahmed F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [40] Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus (vol 22, 185, 2023)
    Lyu, Young Sang
    Oh, Seok
    Kim, Jin Hwa
    Kim, Sang Yong
    Jeong, Myung Ho
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
12345